Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C

Thrombosis and Haemostasis

Volumn 82, Issue 5, 1999, Pages 1462-1468

  Fernández, José A ^a   Petäjä, Jari ^a   Griffin, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Activated protein C; Dermatan sulfate; Factor V; Heparin

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; CERTOPARIN; DALTEPARIN; DERMATAN SULFATE; ENOXAPARIN; GLYCOSAMINOGLYCAN; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; POLYSACCHARIDE; TINZAPARIN;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION;

EID: 0032729026     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614856     Document Type: Article

References (27)

1. Schoen P, Lindhout T, Willems G, Hemker HC. Antithrombin III-dependent antiprothrombinase activity of heparin and heparin fragments. J Biol Chem 1989; 264: 10002-7.
2. Barrowcliffe TW, Thomas DP. Anticoagulant activities of heparin and fragments. Ann N Y Acad Sci 1989; 556: 132-45.
3. Baruch D, Lindhout T, Wagenvoord R, Hemker HC. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of Antithrombin III. Haemostasis 1986; 16: 71-81.
4. Nader HB, Dietrich CP. Natural occurrence, and possible biological role of heparin. In: Heparin. Chemical and Biological Properties and Clinical Applications. Lane DA, Lindahl U. eds. Boca Raton: CRC Press, Inc. 1989; 81-96.
5. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40: 498-530.
6. Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ashan A. Preclinical studies on a low molecular weight heparin. Thromb Res 1996; 81: 1-27.
7. Petäjä J, Fernández JA, Gruber A, Griffin JH. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of degradation of factor V by activated protein C. J Clin Invest 1997; 99: 2655-63.
8. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of activated human factor VIII procoagulant protein by activated protein C and its analogy to factor V. Blood 1984; 63: 486-9.
9. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-45.
10. Naggi A, Torri G, Casu B, Pangrazzi J, Abbadini M, et al. "Supersulfated" heparin fragments, a new type of low molecular weight heparin. Biochem Pharmacol 1987; 36: 1895-1900.
11. Hackeng TM, van t' Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
12. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH. Antithrombotic effects of combining activated protein C and urokinase in non-human primates. Circulation 1991; 84: 2454-62.
13. 506 → glutamine mutation. Stroke 1996; 27: 1163-6.
14. Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-800.
15. Barrow RT, Healey JF, Lollar P. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J Biol Chem 1994; 269: 593-8.
16. Suzuki K, Nishioka J, Kusumoto H, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem 1984; 95: 187-95.
17. España F, Berretini M, Griffin JH. Purification and characterization of plasma protein C inhibitor. Thromb Res 1989; 55: 369-84.
18. Atha DH, Stephens AW, Rosenberg RD. Evaluation of critical groups required for the binding of heparin to Antithrombin. Proc Natl Acad Sci USA 1984; 81: 1030-4.
19. Ofosu FA, Choay J, Anvari N, Smith LM, Blajchman MA. Inhibition of factor X and factor V activation by dermatan sulfate a pentasaccharide with high affinity for Antithrombin III in human plasma. Eur J Biochem 1990; 193: 485-93.
20. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
21. Fernández JA, Petäjä J, Gruber A, Griffin JH. Activated Protein C correlates inversely with thrombin levels in resting healthy individuals. Am J Hematol 1997; 56: 29-31.
22. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996; 81: 29-38.
23. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous Enoxaparin in non-Q-wave coronary events study. N Engl J Med 1997; 337: 447-52.
24. Snow TR, Deal MT, Dickey DT, Esmon CT. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation 1991; 84: 293-9.
25. Bianchini P, Bergonzini GL, Parma B, Osima B. Relationship between plasma antifaclor Xa activity and the antithrombotic activity of heparins of different molecular mass. Haemostasis 1995; 25: 288-98.
26. Delorme MA, Tam ASK, Xu L. The effects of dermatan sulfate at submicrogram/ml concentrations on in vitro thrombin generation. Thromb Haemost 1996; 75: 747-51.
27. Andrew M, Mitchell L, Berry L, Paes B, Delorme M, et al. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992; 89: 321-6.